You are here

Mesenchymal Stem Cells

Exosomal CNP Promotes Recovery of Damaged Brain

Mesenchymal stem cells (MSCs) have vast therapeutic potential for the treatment for neurological diseases and damage, with many of their effects mediated by components of the stem cell secretome.

Mitochondrial Transfer from MSCs to Islet β-cells

Mesenchymal stem cells (MSCs) have direct effects on islet β‐cells that improve their insulin secretory function, and studies have highlighted the essential nature of the generation of ATP and other metabolic coupling factors by mitochondrial metabolism for nutrient‐induced insulin secretion.

Stem Cell Therapies Affect Clotting following Trauma

While various stem cell-based therapeutics are currently under investigation as a treatment option following trauma, such as brain or lung injury, stem cells readily express tissue factor (TF), which causes rapid blood clotting.

MSC-polarized Macrophages Alleviate Diabetic Nephropathy

While mesenchymal stem cells (MSCs) have been reported to prevent renal injuries via immune regulation in diabetic models, the mechanisms at play remain to be fully elucidated.

Phase III Trial of Autologous MSCs for Perianal Fistula

MSC-Induced Kidney Transplant Tolerance

A case report published in STEM CELLS Translational Medicine 

MSC Therapy for Osteogenesis Imperfecta Treatment

A new STEM CELLS article from the lab of Ivo Kalajzic (UConn Health, Farmington, Connecticut, USA) recently presented a novel translational approach for the treatment of osteogenesis imperfecta (OI).

Identifying an Optimal Meniscus‐derived Stem Cell Population for Regenerative Approaches

Researchers define an optimal population of rat meniscus tendon tissue-derived mesenchymal stem cells for use in meniscus repair and osteoarthritis suppression

Reviewing Stem Cell Therapies for OA

Despite the promise of stem cell‐based therapies as a treatment option for osteoarthritis (OA), results have fallen short of expectations.

MSC Trends and Dosing in Clinical Trials

A new study from the lab of Martin Grumet (Rutgers University, Piscataway, NJ, USA) assessed clinical


Subscribe to RSS - Mesenchymal Stem Cells